Screener
Organon OGN SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by Organon in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Organon’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 8:46 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-029532
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Revenues | $1,460 | $1,513 |
| Cost of sales | 677 | 672 |
| Gross profit | 783 | 841 |
| Selling, general and administrative | 424 | 420 |
| Research and development | 93 | 96 |
| Acquired in-process research and development and milestones | — | 6 |
| Restructuring costs | 31 | 86 |
| Interest expense | 111 | 124 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Organon's SG&A?
- Organon (OGN) reported SG&A of $424M in Q1 2026.
- How has Organon's SG&A changed year-over-year?
- Organon's SG&A increased by 1.0% year-over-year, from $420M to $424M.
- What is the long-term trend for Organon's SG&A?
- Over 4 years (2021 to 2025), Organon's SG&A has grown at a 0.8% compound annual growth rate (CAGR), from $1.67B to $1.72B.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Organon's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude